US › Healthcare

Harrow Health Inc (HROW)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$39.83+1.89%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$44.2M
Revenue YoY
-7.6%
Net profit
$-27.6M
Profit YoY
-55.2%
EPS
$-0.74
EPS estimate
$-0.33
Net margin
-62.4%

EPS came in at -0.74 against a street estimate of -0.33 — a miss of 124.2%.

Key statistics

Market cap
$1.46B
Forward P/E
256.4
P/B
50.34
Book value
$0.77
EPS (TTM)
$-0.38
52-week high
$54.85
52-week low
$28.54
50-day MA
$39.37
200-day MA
$41.11
Beta
0.25

Analyst view

Analysts rate Harrow Health Inc a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $67.75.

Shareholding

Insiders
15.47%
Institutions
59.13%

Largest institutional holders

FundStake
Opaleye Management Inc7.60%
BlackRock Inc6.85%
Vanguard Group Inc5.16%
Private Capital Management, LLC4.19%
Vanguard Capital Management, LLC3.76%
Luxor Capital Group, LP3.00%
State Street Corp2.29%
Geode Capital Management, LLC2.29%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Harrow Health Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.